All NICE products on breast cancer. Includes any guidance, advice and quality standards.

NICE recommends the tablets for adults with moderate to severe fibroid symptoms. Linzagolix is recommended for longer-term treatment, with the dose depending on the patient. For endometriosis, they ...

Innovative AI technologies have the potential to act like a ‘second pair of eyes’, helping radiologists review prostate MRI scans.

A significant number of people are discharged after hospital treatment for trauma or orthopaedic surgery with temporary lower limb immobilisation. These people may have an increased risk of VTE, but ...

Lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer’s disease [ID4043] ...

Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (terminated appraisal) Technology appraisal guidance TA987 Published: 10 July 2024 Register as a ...

Note: Healthcare students at universities which have an OpenAthens administrator can have an NHS OpenAthens account for the duration of their course. Students at these universities will have NHS ...

This guideline covers assessing and reducing the risk of venous thromboembolism (VTE or blood clots, including deep vein thrombosis and pulmonary embolism) in people aged 16 and over in hospital. It ...

From blood-based biomarkers to AI-powered tools, discover how 9 innovations are being tested in the NHS to speed up dementia diagnosis.

This guideline covers diagnosing and managing dementia (including Alzheimer’s disease). It aims to improve care by making recommendations on training staff and helping carers to support people living ...

This guide describes the methods and processes, including expected timescales, that NICE follows when carrying out health technology evaluations. The methods and processes are designed to produce ...

Evidence-based recommendations on dabrafenib (Tafinlar) plus trametinib (Mekinist) for BRAF V600 mutation-positive advanced non-small-cell lung cancer in adults. There is a commercial access agreement ...